<P><B>Abstract</B></P> <P>Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to ∼400 million infections and ∼100 million dengue cases each year. Factors that contribute to protection f...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107520900
Katzelnick, Leah C. ; Harris, Eva ; Baric, Ralph ; Coller, Beth-Ann ; Coloma, Josefina ; Crowe Jr., James E. ; Cummings Jr., Derek A.T. ; Dean Jr., Hansi ; de Silva Jr., Aravinda ; Diamond Jr., Michael S. ; Durbin Jr., Anna ; Ferguson Jr., Neil ; Gilbert Jr., Peter B. ; Gordon Jr., Aubree ; Gubler Jr., Duane J. ; Guy Jr., Bruno ; Halloran Jr., M. Elizabeth ; Halstead Jr., Scott ; Jackson Jr., Nicholas ; Jarman Jr., Richard ; Lok Jr., Shee-mei ; Michael Jr., Nelson L. ; Ooi Jr., Eng Eong ; Papadopoulos Jr., Athanasios ; Plotkin Jr., Stanley ; Precioso Jr., Alexander R. ; Reiner Jr., Robert ; Rey Jr., Felix A. ; Rodrí ; guez-Barraquer Jr., Isabel ; Rothman Jr., Alan ; Schmidt Jr., Alexander C. ; Screaton Jr., Gavin ; Sette Jr., Alessandro ; Simmons Jr., Cameron ; St. John Jr., Ashley L. ; Sun Jr., Wellington ; Thomas Jr., Stephen ; Torresi Jr., Joseph ; Tsang Jr., John S. ; Vannice Jr., Kirsten ; Whitehead Jr., Stephen ; Wilder-Smith Jr., Annelies ; Kyu Yoon Jr., In
2017
-
SCI,SCIE,SCOPUS
학술저널
4659-4669(11쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
<P><B>Abstract</B></P> <P>Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to ∼400 million infections and ∼100 million dengue cases each year. Factors that contribute to protection f...
<P><B>Abstract</B></P> <P>Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to ∼400 million infections and ∼100 million dengue cases each year. Factors that contribute to protection from and risk of dengue and severe dengue disease have been studied extensively but are still not fully understood. Results from Phase 3 vaccine efficacy trials have recently become available for one vaccine candidate, now licensed for use in several countries, and more Phase 2 and 3 studies of additional vaccine candidates are ongoing, making these issues all the more urgent and timely. At the “<I>Summit on Dengue Immune Correlates of Protection</I>”, held in Annecy, France, on March 8–9, 2016, dengue experts from diverse fields came together to discuss the current understanding of the immune response to and protection from DENV infection and disease, identify key unanswered questions, discuss data on immune correlates and plans for comparison of results across assays/consortia, and propose a research agenda for investigation of dengue immune correlates, all in the context of both natural infection studies and vaccine trials.</P>